Immatics (NASDAQ:IMTX) Price Target Raised to $16.00 at Mizuho

Immatics (NASDAQ:IMTXFree Report) had its price target upped by Mizuho from $14.00 to $16.00 in a research note published on Thursday morning, Benzinga reports. They currently have a buy rating on the stock.

Immatics Stock Up 1.4 %

NASDAQ:IMTX opened at $10.96 on Thursday. The business’s 50-day moving average price is $10.89 and its 200 day moving average price is $10.67. Immatics has a 52-week low of $7.15 and a 52-week high of $13.16. The firm has a market cap of $927.87 million, a P/E ratio of -10.34 and a beta of 0.69.

Immatics (NASDAQ:IMTXGet Free Report) last announced its quarterly earnings data on Thursday, March 21st. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.09. Immatics had a negative net margin of 107.80% and a negative return on equity of 29.36%. The company had revenue of $17.14 million for the quarter, compared to analysts’ expectations of $11.78 million. Sell-side analysts expect that Immatics will post -1.32 EPS for the current year.

Institutional Trading of Immatics

A number of hedge funds have recently bought and sold shares of the company. Trexquant Investment LP increased its position in shares of Immatics by 4.2% in the fourth quarter. Trexquant Investment LP now owns 44,773 shares of the company’s stock worth $471,000 after acquiring an additional 1,801 shares in the last quarter. Exchange Traded Concepts LLC raised its stake in Immatics by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 11,501 shares of the company’s stock valued at $121,000 after purchasing an additional 2,916 shares during the period. Jump Financial LLC raised its stake in Immatics by 19.8% during the 4th quarter. Jump Financial LLC now owns 48,484 shares of the company’s stock valued at $511,000 after purchasing an additional 8,014 shares during the period. Nan Fung Group Holdings Ltd acquired a new stake in Immatics during the 1st quarter valued at $165,000. Finally, ADAR1 Capital Management LLC purchased a new stake in shares of Immatics in the fourth quarter valued at $232,000. 64.41% of the stock is owned by hedge funds and other institutional investors.

Immatics Company Profile

(Get Free Report)

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.

Further Reading

Receive News & Ratings for Immatics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immatics and related companies with's FREE daily email newsletter.